Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months.

Cardiovascular diseases (CVDs) are the key factors leading to death and disability worldwide. This severe challenge has prompted the scientific research and ...

Q4 2024 Earnings Call Transcript February 6, 2025 Zimmer Biomet Holdings, Inc. beats earnings expectations. Reported EPS is $2.31, expectations were $2.3. Operator: Good morning, ladies and gentlemen, ...

For Central Texans who for more than a decade now have blamed SpaceX entrepreneur Elon Musk's thundering rocket-testing ...

A healthy weight loss is a gradual process that does not happen overnight. This is a known fact. But what if this is taking ...

Bryan O’Donnell, Head of Quality at Gaelic Laboratories, explains how to navigate GMP challenges to ensure your company ...

W. Edwards Deming Quality culture is a cornerstone of any industry, particularly the healthcare industry where patient lives ...

The US President's Emergency Plan for AIDS Relief (PEPFAR) faces a pivotal moment, confronting one of its most challenging periods since its launch in 2003. The new policy priorities of the ...